Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genentech, Inc.

http://www.gene.com

Latest From Genentech, Inc.

Seagen, Genmab See Broad Cervical Cancer Opportunity For Tisotumab Vedotin

At ESMO, data showed overall response benefit in combination with carboplatin in first-line therapy, and with Keytruda in second- or third-line treatment. The antibody-drug conjugate obtained US approval on 20 September as monotherapy.

Clinical Trials Research & Development

Hetero To Debut Biosimilar Actemra, Giving India Grasp On Supplies Security

The availability later this month of Hetero's biosimilar tocilizumab, ostensibly a less pricey product, could place India in a relatively better situation to cope with any demand spurt should another wave of COVID-19 strike. Innovator product Actemra is expected to be in short supply, going by current trends, given the unprecedented worldwide demand.

Commercial Coronavirus COVID-19

Coronavirus Notebook: New Deal To Boost Local Vaccine Manufacturing, EU Warns Of RoActemra Shortages

MSF tells G20 leaders to “put your money where your mouth is” on vaccine sharing, the UK is considering whether to vaccinate all 12-15-year olds, and the UK & Australia are to swap excess vaccines.

Asia Pacific Australia

Keytruda's Urothelial Cancer Claim Goes From Accelerated To Full Approval, With More Limited Scope

US FDA showed some regulatory flexibility by relying on longer-term follow-up from Merck’s original single-arm trial, rather than additional confirmatory studies, to retain the first-line claim, but it narrowed the target population to those with the greatest unmet need; Keytruda indication was one of six 'dangling' accelerated approvals re-examined by Oncologic Drugs Advisory Committee in April.

Approvals ImmunoOncology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Tanox
UsernamePublicRestriction

Register